Prescription drug maker GlaxoSmithKline PLC has agreed to pay $750 million to settle federal civil and criminal charges in the nation’s fourth-largest health care fraud settlement. The False Claims Act settlement was announced at a Boston press conference on Tuesday by Assistant U.S. Attorney General Tony West and U.S. Attorney Carmen Ortiz of the District of Massachusetts.

The deal calls for GlaxoSmithKline (GSK) to plead guilty to introducing four types of adulterated drugs for delivery into interstate commerce from March 2003 to October 2004. The drugs were made by GSK subsidiary SB Pharma Puerto Rico at a since-closed Cidra, Puerto Rico, facility.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]